<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25648" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neointimal Hyperplasia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zain</surname>
            <given-names>Muhammad A.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jamil</surname>
            <given-names>Radia T.</given-names>
          </name>
          <aff>Allama Iqbal Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Siddiqui</surname>
            <given-names>Waqas J.</given-names>
          </name>
          <aff>Drexel University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Zain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Radia Jamil declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Waqas Siddiqui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25648.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Atherosclerosis is a leading cause of morbidity and mortality globally, and many interventions are performed to treat it. However, despite the potential benefits of these procedures, they may fail due to restenosis caused by neointimal hyperplasia (NIH). Neointimal hyperplasia refers to post-intervention, pathological, vascular remodeling due to the proliferation and migration of vascular smooth muscle cells in the tunica intima layer, resulting in vascular wall thickening and the gradual loss of luminal patency which may lead to the return of vascular insufficiency symptoms. This activity describes the pathophysiology of neointimal hyperplasia and highlights the role of the interprofessional team in managing these patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of neointimal hyperplasia.</p></list-item><list-item><p>Describe the presenting features of neointimal hyperplasia.</p></list-item><list-item><p>Outline the treatment options available for neointimal hyperplasia.</p></list-item><list-item><p>Explain the importance of optimizing coordination amongst the interprofessional team to enhance care for patients affected by neointimal hyperplasia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25648&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25648">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25648.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Atherosclerosis is a leading cause of morbidity and mortality globally. Currently, many&#x000a0;procedures are performed&#x000a0;by interventionists and vascular surgeons to treat atherosclerosis, such as balloon angioplasty with or without stenting, endarterectomy, or surgical bypass grafting. However, despite the benefits, these interventions fail from restenosis due to neointimal hyperplasia (NIH). In a normal vasculature, smooth muscle cells (SMC) are found in the tunica media, and they are quiescent with minimal turnover and contractile phenotype. Neointimal hyperplasia refers to post-intervention, pathological, vascular remodeling due to the proliferation and migration of vascular smooth muscle cells into the tunica intima layer, resulting in vascular wall thickening and the gradual loss of luminal patency which may lead to the return of vascular insufficiency symptoms. <xref ref-type="bibr" rid="article-25648.r1">[1]</xref><xref ref-type="bibr" rid="article-25648.r2">[2]</xref>&#x000a0;SMC in neointimal hyperplasia lose contractile phenotype, and they differentiate into secretory phenotype predominantly. These modified SMC secrete the growth factors, growth factor receptors, extracellular matrix, proteinases, and inflammatory mediators responsible for neointimal hyperplasia. Many vascular interventions put vessels at risk of injury, leading to restenosis due to activation of the inflammatory cascade and cellular recruitment. It is most evident in "in-stent restenosis" after the plain old balloon angioplasty (POBA) without stenting and percutaneous coronary intervention with bare-metal stenting. Metallic stents were necessary to counteract acute vascular recoil after POBA, but after serving this purpose, long-term in situ metallic platform injure the vascular wall and sets in chronic inflammation and hyperplasia of the vascular intimal layer. Other vascular manipulation also may result in vessel injury, leading to neointimal hyperplasia.</p>
        <p>There are two types of neointimal hyperplasia.</p>
        <list list-type="order">
          <list-item>
            <p>Arterial neointimal hyperplasia secondary to arterial manipulation in endarterectomy or angioplasty.&#x000a0;<xref ref-type="bibr" rid="article-25648.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Venous graft associated neointimal hyperplasia secondary to coronary artery bypass grafting or arteriovenous grafting/ fistula formation.&#x000a0;<xref ref-type="bibr" rid="article-25648.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25648.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Vascular wall injury may be due to manipulation by any of the following procedures:</p>
        <list list-type="bullet">
          <list-item>
            <p>Use of angioplasty catheter and balloon inflation during the angioplasty.</p>
          </list-item>
          <list-item>
            <p>Use of an embolectomy catheter.</p>
          </list-item>
          <list-item>
            <p>Vascular endarterectomy.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Small target veins used in arteriovenous fistula creation.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Coronary vein grafting or coronary artery bypass grafting (CABG).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25648.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <list list-type="bullet">
          <list-item>
            <p>The patency rate of the venous graft used during CABG is 80% at one year and 60% at five years. A saphenous venous graft (SVG) is more prone to intimal hyperplasia and stenosis than an internal mammary artery graft. However, late-onset occlusion of SVG after five years of grafting is almost always due to neo-atherosclerosis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Arteriovenous (AV) fistula or graft is used as a vascular access site for hemodialysis in patients with end-stage renal disease (ESRD) on dialysis. Arteriovenous (AV) fistula or graft failure rate varies between 30% to 60% at one year. Recent studies have indicated that neointimal hyperplasia is the most common underlying pathology in 30% to 60% of AV grafts or fistula failures followed by vascular thrombosis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25648.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The events leading to neointimal hyperplasia can be broadly classified into the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Endothelial dysfunction and activation</p>
          </list-item>
          <list-item>
            <p>Platelet activation and thrombus formation</p>
          </list-item>
          <list-item>
            <p>Leucocyte recruitment</p>
          </list-item>
          <list-item>
            <p>Smooth muscle cell migration and proliferation</p>
          </list-item>
        </list>
        <p>The primary pathology is the proliferation and migration of smooth muscle cells (SMCs) in the tunica intima layer. The triggering step is endothelial damage or dysfunction (ED) due to vascular injury, which can occur secondary to a vascular wall stretching during balloon angioplasty, vascular manipulation during carotid endarterectomy, or venous graft implantation during arteriovenous fistula formation or coronary bypass grafting.&#x000a0;<xref ref-type="bibr" rid="article-25648.r1">[1]</xref> ED leads to endothelial activation and decreases the production of nitrous oxide (NO) due to the dysregulation of endothelial nitric oxide synthase (ENOS). <xref ref-type="bibr" rid="article-25648.r5">[5]</xref><xref ref-type="bibr" rid="article-25648.r6">[6]</xref>&#x000a0;When platelets come in contact with activated endothelial cells, it forms a platelet-rich thrombus. An inflammatory cascade begins at the vascular injury site,&#x000a0;and leukocytes demarginate from the bloodstream and reach sub-endothelial thrombus. Oxidative stress promotes the expression of endothelial adhesion molecules, such as vascular cell adhesion molecules, that help recruitment and migration of monocytes into the subendothelial area.&#x000a0;<xref ref-type="bibr" rid="article-25648.r7">[7]</xref><xref ref-type="bibr" rid="article-25648.r2">[2]</xref></p>
        <p>Matrix metalloproteinases are key enzymes that cause the breakdown of extracellular matrix proteins, such as collagen and elastin, and facilitate the migration of vascular SMCs across internal elastic lamina in neointimal hyperplasia formation.&#x000a0;<xref ref-type="bibr" rid="article-25648.r8">[8]</xref>It is also noted in arteriovenous grafts studies that SMCs can alternately originate from fibroblasts from vascular adventitia or bone marrow progenitor cells.&#x000a0;<xref ref-type="bibr" rid="article-25648.r2">[2]</xref><xref ref-type="bibr" rid="article-25648.r9">[9]</xref> Once SMCs migrate at the vascular injury site intimal layer, they go through a phenotypic transition from predominantly contractile to secretory type SMCs.</p>
      </sec>
      <sec id="article-25648.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In both arterial and venous neointimal hyperplasia, there is SMC and fibroblast accumulation in the tunica intima layer with extracellular matrix (ECM) or collagen deposition. On immunohistochemistry studies, vascular samples with neointimal hyperplasia show multi-layered SMCs, which stain positive for alpha-smooth muscle actin, endothelial cells staining positive for anti-von Willebrand factor antibodies, fibroblasts which secrete ECM, lymphocytes, and macrophages. The excessive cellular deposition results in the expansion of the intimal layer and loss of the luminal area.&#x000a0;<xref ref-type="bibr" rid="article-25648.r10">[10]</xref> Tunica media layer in arterial neointimal hyperplasia tends to remain thin despite the increased thickness of the intimal layer. This is in contrast to vein graft adaptation, where there is also a concurrent expansion of the tunica media layer.&#x000a0;<xref ref-type="bibr" rid="article-25648.r4">[4]</xref><xref ref-type="bibr" rid="article-25648.r11">[11]</xref><xref ref-type="bibr" rid="article-25648.r12">[12]</xref><xref ref-type="bibr" rid="article-25648.r13">[13]</xref></p>
      </sec>
      <sec id="article-25648.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Neointimal hyperplasia may be associated with recurrence of symptoms such as.</p>
        <list list-type="bullet">
          <list-item>
            <p>Anginal symptoms or acute coronary syndrome for coronary artery venous graft or stenting with critical flow-limiting graft stenosis.</p>
          </list-item>
          <list-item>
            <p>AV graft&#x000a0;or fistula failure leading to vascular access complication and delayed hemodialysis in ESRD patients on hemodialysis.</p>
          </list-item>
          <list-item>
            <p>Post carotid&#x000a0;endarterectomy&#x000a0;(CEA) restenosis due to neointimal hyperplasia can present with a transient ischemic attack (TIA) or stroke symptoms.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25648.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Workup should include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Angiography</p>
          </list-item>
          <list-item>
            <p>Intravascular ultrasonography</p>
          </list-item>
          <list-item>
            <p>Intravascular optical coherence&#x000a0;tomography and correlation with histological findings of neointimal hyperplasia</p>
          </list-item>
          <list-item>
            <p>Flow Doppler&#x000a0;catheters to document flow limitation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Graft surveillance&#x000a0;to detect and repair neointimal hyperplasia early</p>
          </list-item>
          <list-item>
            <p>Carotid Doppler&#x000a0;ultrasonography</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25648.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Pharmacotherapy targeted at different&#x000a0;steps of the pathogenesis of neointimal hyperplasia can be used to prevent and treat this condition. Graft surveillance in high-risk patients with serial Doppler ultrasound within the first&#x000a0;two years after the vascular intervention can detect and repair neointimal hyperplasia.&#x000a0;<xref ref-type="bibr" rid="article-25648.r10">[10]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Platelet activation and thrombus formation: </bold>Aspirin, P2Y12 (clopidogrel), glycoprotein IIb/IIIa inhibitors (abciximab), heparin, or hirudin targets this step to prevent neointimal hyperplasia.</p>
          </list-item>
          <list-item>
            <p><bold>Leucocyte recruitment: </bold>Probucol is an antioxidant that prevents neointimal hyperplasia by blocking leukocytes recruitment into the sub-endothelial area of an injured vascular wall.</p>
          </list-item>
          <list-item>
            <p>
<bold>SMC migration&#x000a0;and proliferation:</bold>
</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>NO deficiency secondary to ED has been linked with the neointimal hyperplasia&#x000a0;development. Local NO-based perivascular&#x000a0;powder therapy and poly (diol-co-citrate) elastomeric vascular wraps are superior to systemic NO therapies, which have adverse outcomes.&#x000a0;<xref ref-type="bibr" rid="article-25648.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Drug-eluting stents (DES) containing paclitaxel or everolimus also blocks SMC migration and proliferation. DES recently&#x000a0;has&#x000a0;been used in post-carotid endarterectomy restenosis cases in addition to their&#x000a0;well-known use in coronary angioplasty with stenting.&#x000a0;<xref ref-type="bibr" rid="article-25648.r15">[15]</xref><xref ref-type="bibr" rid="article-25648.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Gene therapy targeting SMC migration,&#x000a0;proliferation, and NO production have also been studied.</p>
          </list-item>
          <list-item>
            <p>Beta vascular brachytherapy has been proven to reduce neointimal hyperplasia burden after a few months.&#x000a0;<xref ref-type="bibr" rid="article-25648.r17">[17]</xref><xref ref-type="bibr" rid="article-25648.r18">[18]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25648.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The following conditions can present similarly and need to be considered along with neointimal hyperplasia:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neoatherosclerosis</p>
          </list-item>
          <list-item>
            <p>Late stent thrombosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25648.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Determination of neointimal characteristics is&#x000a0;useful in predicting long-term clinical outcomes. Data suggests that heterogeneous lesions are linked to poor long-term clinical prognoses.</p>
      </sec>
      <sec id="article-25648.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Depending on the organ system involved, vascular insufficiency can lead to the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>The recurrence of angina or acute myocardial infarction.</p>
          </list-item>
          <list-item>
            <p>AV fistula or graft failure, which leads to a delay in hemodialysis due to loss of vascular access.</p>
          </list-item>
          <list-item>
            <p>Transient ischemic attacks or cerebrovascular accident due to post carotid endarterectomy restenosis or thrombosis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25648.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Multidisciplinary team consultation may be required with the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Interventional cardiologists</p>
          </list-item>
          <list-item>
            <p>Cardiothoracic surgeons</p>
          </list-item>
          <list-item>
            <p>Interventional radiologists</p>
          </list-item>
          <list-item>
            <p>Vascular surgeons</p>
          </list-item>
          <list-item>
            <p>Oncologists</p>
          </list-item>
          <list-item>
            <p>Rehabilitation team members</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25648.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>To improve patient outcomes, the key is to prevent this disease process in the first place. This means patient education about the benefits of exercise, smoking discontinuation, eating a healthy diet, and not leading a sedentary lifestyle.</p>
      </sec>
      <sec id="article-25648.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Atherosclerosis can affect almost any vessel and lead to obstruction of blood flow. To improve patient outcomes, the key is to prevent this disease process in the first place. This means patient education about the benefits of exercise, smoking discontinuation, eating a healthy diet, and not leading a sedentary lifestyle.</p>
        <p>Healthcare workers, including the pharmacist and nurse, have to monitor the patient's body weight, lipid levels, blood sugar, and blood pressure regularly. When conservative methods fail to control these parameters, drug therapy may be in order.</p>
      </sec>
      <sec id="article-25648.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25648&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25648">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/neointimal-hyperplasia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25648">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25648/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25648">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25648.s17">
        <title>References</title>
        <ref id="article-25648.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonatti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oberhuber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schachner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hammerer-Lercher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mittermair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Laufer</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Neointimal Hyperplasia in Coronary Vein Grafts: Pathophysiology and Prevention of a Significant Clinical Problem.</article-title>
            <source>Heart Surg Forum</source>
            <year>2004</year>
            <month>Jan</month>
            <day>01</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-87</page-range>
            <pub-id pub-id-type="pmid">14980855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shoji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Roles of bone-marrow-derived cells and inflammatory cytokines in neointimal hyperplasia after vascular injury.</article-title>
            <source>Biomed Res Int</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>945127</fpage>
            <pub-id pub-id-type="pmid">24551856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Subbotin</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>Analysis of arterial intimal hyperplasia: review and hypothesis.</article-title>
            <source>Theor Biol Med Model</source>
            <year>2007</year>
            <month>Oct</month>
            <day>31</day>
            <volume>4</volume>
            <fpage>41</fpage>
            <pub-id pub-id-type="pmid">17974015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shenoy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Allon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beathard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brouwer-Maier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dember</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Glickman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Litchfield</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lok</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Roy-Chaudhury</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Work</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wasse</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical Trial End Points for Hemodialysis Vascular Access: Background, Rationale, and Definitions.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>07</day>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>490</fpage>
            <page-range>490-494</page-range>
            <pub-id pub-id-type="pmid">29487092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lavin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pello</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Castejon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Piedras</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Saura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zaragoza</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Nitric oxide prevents aortic neointimal hyperplasia by controlling macrophage polarization.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>1739</fpage>
            <page-range>1739-46</page-range>
            <pub-id pub-id-type="pmid">24925976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahnson</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cantu-Medellin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tsui</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Havelka</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Vercammen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Kibbe</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Nitric oxide inhibits neointimal hyperplasia following vascular injury via differential, cell-specific modulation of SOD-1 in the arterial wall.</article-title>
            <source>Nitric Oxide</source>
            <year>2015</year>
            <month>Jan</month>
            <day>30</day>
            <volume>44</volume>
            <fpage>8</fpage>
            <page-range>8-17</page-range>
            <pub-id pub-id-type="pmid">25460325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nagel</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Cygnar</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Role of cAMP-phosphodiesterase 1C signaling in regulating growth factor receptor stability, vascular smooth muscle cell growth, migration, and neointimal hyperplasia.</article-title>
            <source>Circ Res</source>
            <year>2015</year>
            <month>Mar</month>
            <day>27</day>
            <volume>116</volume>
            <issue>7</issue>
            <fpage>1120</fpage>
            <page-range>1120-32</page-range>
            <pub-id pub-id-type="pmid">25608528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rotmans</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Velema</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Verhagen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Blankensteijn</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>de Kleijn</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Stroes</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Pasterkamp</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model.</article-title>
            <source>J Vasc Surg</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>432</fpage>
            <page-range>432-9</page-range>
            <pub-id pub-id-type="pmid">14743149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guthrie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Long-term engraftment of bone marrow-derived cells in the intimal hyperplasia lesion of autologous vein grafts.</article-title>
            <source>Am J Pathol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>172</volume>
            <issue>3</issue>
            <fpage>839</fpage>
            <page-range>839-48</page-range>
            <pub-id pub-id-type="pmid">18276778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collins</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Protack</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Muto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jadlowiec</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dardik</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic strategies to combat neointimal hyperplasia in vascular grafts.</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2012</year>
            <month>May</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>635</fpage>
            <page-range>635-47</page-range>
            <pub-id pub-id-type="pmid">22651839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Roy-Chaudhury</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis.</article-title>
            <source>Adv Chronic Kidney Dis</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>329</fpage>
            <page-range>329-38</page-range>
            <pub-id pub-id-type="pmid">19695501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Terry</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Kuji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Masaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Zhuplatov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>3139</fpage>
            <page-range>3139-46</page-range>
            <pub-id pub-id-type="pmid">17602194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitra</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Gangahar</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia.</article-title>
            <source>Immunol Cell Biol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-24</page-range>
            <pub-id pub-id-type="pmid">16519729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serrano</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vavra</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Jen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hogg</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Murar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keefer</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ameer</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Kibbe</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Poly(diol-co-citrate)s as novel elastomeric perivascular wraps for the reduction of neointimal hyperplasia.</article-title>
            <source>Macromol Biosci</source>
            <year>2011</year>
            <month>May</month>
            <day>12</day>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>700</fpage>
            <page-range>700-9</page-range>
            <pub-id pub-id-type="pmid">21341372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Del Giudice</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pellerin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gandini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sapoval</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Commentary: drug-coated balloon angioplasty to improve carotid stenting outcomes after postendarterectomy restenosis: fad or an answer to the problem of recurrent restenosis?</article-title>
            <source>J Endovasc Ther</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>217</fpage>
            <page-range>217-9</page-range>
            <pub-id pub-id-type="pmid">25809365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Bush</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Peden</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Guerrero</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kougias</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lumsden</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Management of in-sent restenosis after carotid artery stenting in high-risk patients.</article-title>
            <source>J Vasc Surg</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>305</fpage>
            <page-range>305-12</page-range>
            <pub-id pub-id-type="pmid">16476606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Werner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scheinert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Henn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scheinert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Br&#x000e4;unlich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bausback</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Friedenberger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hertting</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Piorkowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ulrich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gutberlet</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Endovascular brachytherapy using liquid Beta-emitting rhenium-188 for the treatment of long-segment femoropopliteal in-stent stenosis.</article-title>
            <source>J Endovasc Ther</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>467</fpage>
            <page-range>467-75</page-range>
            <pub-id pub-id-type="pmid">22891824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25648.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dheer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dutta</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Intracoronary Radiation.</article-title>
            <source>Med J Armed Forces India</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-9</page-range>
            <pub-id pub-id-type="pmid">27407488</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
